Personalized addition of LH in ovarian stimulation for infertility treatment
Official title: PErsonalized Addition of Recombinant LH in Suboptimal Responders >35 Years Old (POSEIDON Group 2): A Randomized Controlled Trial
Run by Fundacion Dexeus · NCT04719000 · Data updated 2026-11-12
This study is testing if adding a hormone called LH to the usual fertility treatment can help women aged 35 to 40 have better chances of getting pregnant through IVF.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 35 Years to 40 Years |
| Sex | Women only |
| Enrollment | 120 (estimated) |
| Sponsor | Fundacion Dexeus Academic / other |
| Locations | 1 site (Barcelona) |
| Status | Recruiting |
| Started | February 4, 2021 |
| Main results expected | August 2027 |
| Study ends | November 2027 |
| Registry record updated | March 30, 2026 |
| Trial ID | NCT04719000 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are women aged 35 to 40 with a moderate ovarian reserve and a history of limited oocyte retrieval in previous IVF/ICSI cycles.
✕Probably not a fit
Patients who are poor responders according to Bologna criteria or those with PCOS may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial investigates the effects of adding recombinant LH to ovarian stimulation regimens in women undergoing IVF/ICSI. The study aims to optimize hormonal profiles during the late follicular phase to improve implantation rates by analyzing the progesterone/estrogen ratio. Participants will be women aged 35 to 40 with specific ovarian response criteria, and the trial will compare outcomes between those receiving rhFSH alone and those receiving a combination of rhFSH and rhLH. The goal is to enhance the success rates of assisted reproductive technology by tailoring hormonal treatments based on individual responses.
Why it matters
Potential benefit: If successful, this approach could lead to improved pregnancy rates for women undergoing IVF/ICSI by optimizing hormonal conditions.
How similar studies have gone: Other studies have shown varying success with similar hormonal optimization approaches, but this specific combination is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Able and willing to sign the Patient Consent Form and adhere to study visitation schedule. * ≥ 35 years ≤40 years old. * AFC ≥5 and or AMH ≥1.2 ng/mL. * \<4 or 4-9 oocytes retrieved in a previous IVF/ICSI cycle with a starting dose of ≤225 IU with any gonadotropin under a GnRH antagonist protocol. * Up to 3 previous ovarian stimulation cycles with a starting dose of ≤225 IU in which dose adjustments during stimulation did not exceed 300 IU. * Ovarian stimulation for IVF/ICSI Exclusion Criteria: * Poor ovarian responders according to the Bologna criteria. * Polycystic ovary syndrome (PCOS) patients according to the Rotterdam criteria. * AFC\>20. * Age \>40 or \<35 years old. * Women with \>10 oocytes retrieved in a previous IVF/ICSI cycle with 150-225 IU starting dose. * Women who required dose adjustments during stimulation \>300 IU with any gonadotropin in their previous cycle * Uterine abnormalities. * Recent history of any current untreated endocrine abnormality. * Unilateral or bilateral hydrosalpinx (visible on ultrasound scan (USS), unless clipped). * Contraindications for the use of medicine used for ovarian stimulation (gonadotropins, GnRH antagonist, progesterone vaginal gel) * Recent history of severe disease requiring regular treatment (Clinically significant concurrent medical condition that could compromise subject safety or interfered with the trial assessment and patients with any contraindication to pregnancy). * Preimplantation Genetic Testing for Aneuploidies (PGT-a). * Testicular Sperm Aspiration or Testicular Sperm Extraction (TESA or TESE)
Where it's running
-
Hospital Universitario Quiron Dexeus
Barcelona, Spain Recruiting
Study contacts
- Study coordinator: Nikolaos P Polyzos, MD PhD
- Email: nikpol@dexeus.com
- Phone: 0034932274700
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AI-assisted embryo selection on day 5 in IVF for infertility
This trial tests whether an AI-based embryo selection tool can help pick the best embryo for transfer on day 5 in IVF/ICSI to improve pregnancy chances for people with infertility.
-
Preserving sperm quality with aging through cryopreservation
This study tests whether freezing and thawing sperm can help keep younger-like DNA and molecular traits in men as they age.
-
Unstimulated Egg Retrieval with CAPA-IVM and Euploid Embryo Transfer
This study tests whether eggs can be collected without ovarian stimulation, matured in the lab, and used to create a single euploid embryo for transfer in infertility patients.
-
Ultra-Long GnRH-a Pretreatment Before Frozen Embryo Transfer for Deep Infiltrating Endometriosis
In people under 40 with deep infiltrating endometriosis and infertility, the study tests whether two injections of a GnRH agonist before hormone support improve pregnancy outcomes in their first frozen-thawed embryo transfer.
-
Endometrial Waves and Pregnancy in FET Cycles with Hormone Therapy
This study tests whether patterns of uterine contractions during hormone-prepared frozen embryo transfer affect pregnancy outcomes.
-
Environmental and lifestyle factors linked to ART success in infertility patients
This study follows 5,000 infertile men and women to see how environmental exposures and lifestyle relate to the success of assisted reproductive technology.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.